Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside

被引：46
|
作者：
Bruno, B
Giaccone, L
Rotta, M
Anderson, K
Boccadoro, M
机构：
[1] Univ Turin, Div Ematol, Osped S Giovanni Battist, I-10126 Turin, Italy
[2] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
LEUKEMIA | 2005年 / 19卷 / 10期
关键词：
mutliple myeloma; new drugs; signaling pathways;
D O I：
10.1038/sj.leu.2403905
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multiple myeloma remains an incurable plasma cell neoplasm. New insights into its pathogenesis have identified signaling pathways that have become potential therapeutic targets. It has clearly been established that intracellular regulatory proteins and interactions between malignant plasma cells and the bone marrow microenvironment play an important role in their survival and drug resistance. Several new agents associated with molecular targets are currently being investigated to design new treatment strategies aimed at prolonging survival and improving quality of life. This review illustrates their mechanisms of action and the possible future clinical applications.
引用
收藏
页码：1729 / 1738
页数：10
相关论文
共 50 条
  • [21] Targeted Radiotherapeutics from 'Bench-to-Bedside'
    Muller, Cristina
    Behe, Martin
    Geistlich, Susanne
    van der Meulen, Nicholas P.
    Schibli, Roger
    CHIMIA, 2020, 74 (12) : 939 - 945
  • [22] Minimal residual disease in multiple myeloma: bringing the bench to the bedside
    Mailankody, Sham
    Korde, Neha
    Lesokhin, Alexander M.
    Lendvai, Nikoletta
    Hassoun, Hani
    Stetler-Stevenson, Maryalice
    Landgren, Ola
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (05) : 286 - U139
  • [23] Minimal residual disease in multiple myeloma: bringing the bench to the bedside
    Sham Mailankody
    Neha Korde
    Alexander M. Lesokhin
    Nikoletta Lendvai
    Hani Hassoun
    Maryalice Stetler-Stevenson
    Ola Landgren
    Nature Reviews Clinical Oncology, 2015, 12 : 286 - 295
  • [24] Multiple Sclerosis - From Bench to Bedside
    Baker, David
    Amor, Sandra
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2012, 11 (05) : 495 - 496
  • [25] Combining drugs and radiotherapy: from the bench to the bedside
    Palanichamy, Kamalakannan
    Chakravarti, Arnab
    CURRENT OPINION IN NEUROLOGY, 2009, 22 (06) : 625 - 632
  • [26] Repurposing drugs for glioblastoma: From bench to bedside
    Basso, Joao
    Miranda, Ana
    Sousa, Joao
    Pais, Alberto
    Vitorino, Carla
    CANCER LETTERS, 2018, 428 : 173 - 183
  • [27] Targeted proteomics: Bench to bedside
    Nita-Lazar, Aleksandra
    Goodlett, David R.
    JOURNAL OF PROTEOMICS, 2018, 189 : III - IV
  • [28] Novel drugs for the treatment of multiple myeloma: Mechanisms and targets
    Lentzsch, S.
    ONKOLOGIE, 2010, 33 : 19 - 19
  • [29] Targeted Cancer Therapy: From Bench to Bedside to Patient
    Gellad, Walid F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) : 268 - 270
  • [30] Bedside to Bench to Bedside in Multiple Sclerosis
    Voskuhl, Rhonda
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 3 - 3
12345